Category: Drug industry

1 9/2/2015

Bankrupted by cancer: Why “cost” is an important criterion in our review process

1 8/21/2015

Roundup of flibanserin – ‘female Viagra’ – approval news; ‘game changer’ to some, ‘monumental bamboozlement’ for others

4 8/19/2015

What if we had an election and counted only half the ballots? When you’re burying research you’re also likely burying patients

3 7/27/2015

Fred Hutch president predicts cancer cure in 10 years; critics have heard it all before


Taking stock of new Alzheimer’s drug coverage: A “landmark breakthrough” that offers no “clinically apparent benefit”


Harvard’s Jerry Avorn warns against FDA loosening off-label marketing restrictions

4 6/25/2015

Vyvanse – A life cycle drug? Or disease mongering?

10 6/5/2015

Astroturfers rule the day: FDA’s flibanserin reviewers were “emotionally blackmailed” by a slick lobbying campaign

3 6/3/2015

Pink Viagra may be coming soon (but for teetotalers, only!)


Former NEJM editors slam “backtrack” on conflict of interest